Overview

Efficacy and Safety of Pracytarabine Versus Regorafenib in the Treatment of Patients With Hepatocellular Carcinoma

Status:
ACTIVE_NOT_RECRUITING

Trial end date:
2027-04-30

Target enrollment:

Participant gender:

Summary

This is a Phase 2/3 study evaluating the efficacy and safety of pelareorep versus regorafenib in patients with advanced hepatocellular carcinoma (HCC) who have experienced treatment failure with standard systemic therapies involving targeted drugs and immune checkpoint inhibitors, or dual immune checkpoint inhibitors.

Phase:

PHASE2

Details

Lead Sponsor:

Xi'an Xintong Pharmaceutical Research Co.,Ltd.

Treatments:

regorafenib